Should I buy or sell Applied Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLT shares. View APLT analyst ratings or view top-rated stocks .

What is Applied Therapeutics' stock price target for 2024?

5 analysts have issued twelve-month price targets for Applied Therapeutics' stock. Their APLT share price targets range from $7.00 to $14.00. On average, they expect the company's stock price to reach $11.60 in the next year. This suggests a possible upside of 140.2% from the stock's current price. View analysts price targets for APLT or view top-rated stocks among Wall Street analysts .

How have APLT shares performed in 2024?

Applied Therapeutics' stock was trading at $3.35 on January 1st, 2024. Since then, APLT shares have increased by 44.2% and is now trading at $4.83. View the best growth stocks for 2024 here .

Are investors shorting Applied Therapeutics?

Applied Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,980,000 shares, an increase of 31.4% from the March 15th total of 3,790,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is presently 2.4 days. View Applied Therapeutics' Short Interest .

When is Applied Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our APLT earnings forecast .

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.18. The firm had revenue of ($0.67) million for the quarter.

What ETF holds Applied Therapeutics' stock?

Simplify Propel Opportunities ETF holds 2,817,505 shares of APLT stock, representing 14.71% of its portfolio.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD) , Pfizer (PFE) , Advanced Micro Devices (AMD) , Energy Transfer (ET) , Micron Technology (MU) , NVIDIA (NVDA) , Verizon Communications (VZ) , AbbVie (ABBV) , Walt Disney (DIS) and RTX (RTX) .

When did Applied Therapeutics IPO?

Applied Therapeutics (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

How do I buy shares of Applied Therapeutics?

Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:APLT

Applied Therapeutics (APLT) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free APLT Stock Alerts

$4.83

-0.32 (-6.21%)

(As of 04/17/2024 ET)

Compare

Today's Range: $4.65
▼
$5.23
50-Day Range: $2.68
▼
$7.40
52-Week Range: $0.85
▼
$9.39

Volume: 859,052 shs
Average Volume: 1.99 million shs
Market Capitalization: $511.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.60

Get Applied Therapeutics alerts:

Applied Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 140.2% Upside
$11.60 Price Target
Short Interest: Healthy
4.70% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: 0.51
Based on 8 Articles This Week
Insider Trading: Selling Shares
$2.47 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.53) to ($0.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.74 out of 5 stars

Medical Sector

56th out of 914 stocks

Biotechnology Industry

3rd out of 54 stocks

4.5

Analyst's Opinion

Consensus Rating
Applied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Applied Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
4.70% of the outstanding shares of Applied Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Applied Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Applied Therapeutics has recently increased by 31.40%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Applied Therapeutics does not currently pay a dividend.
Dividend Growth
Applied Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Applied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Applied Therapeutics is -0.88.

2.5

News and Social Media Coverage

News Sentiment
Applied Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Applied Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.
MarketBeat Follows
Only 10 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,469,181.00 in company stock.
Percentage Held by Insiders
19.10% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Applied Therapeutics are expected to grow in the coming year, from ($0.53) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Applied Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About Applied Therapeutics Stock (NASDAQ:APLT)

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

APLT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APLT Stock News Headlines

March 19, 2024 | insidertrades.com

Insider Selling: Applied Therapeutics, Inc. (NASDAQ:APLT) CFO Sells 28,727 Shares of Stock

March 19, 2024 | insidertrades.com

Applied Therapeutics, Inc. (NASDAQ:APLT) CEO Shoshana Shendelman Sells 318,573 Shares

April 17, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

April 15, 2024 | americanbankingnews.com

Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update

April 15, 2024 | globenewswire.com

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

April 14, 2024 | markets.businessinsider.com

RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)

April 13, 2024 | americanbankingnews.com

Applied Therapeutics (NASDAQ:APLT) Rating Reiterated by Royal Bank of Canada

April 6, 2024 | investing.com

Applied Therapeutics reveals Phase 3 data on heart drug

April 17, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

April 4, 2024 | finance.yahoo.com

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

April 3, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)

April 1, 2024 | benzinga.com

FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease

April 1, 2024 | benzinga.com

Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket

March 29, 2024 | markets.businessinsider.com

Applied Therapeutics Says FDA Extends Review Period Of NDA For Govorestat

March 28, 2024 | finance.yahoo.com

UPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drug

March 28, 2024 | reuters.com

US FDA extends review of Applied Therapeutics' genetic disease drug

March 28, 2024 | globenewswire.com

Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

March 20, 2024 | investing.com

Applied therapeutics CCO sells shares worth over $263k

March 20, 2024 | investing.com

Applied therapeutics CFO sells shares worth over $150k

March 8, 2024 | finance.yahoo.com

Applied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical Progress

March 6, 2024 | globenewswire.com

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Applied Therapeutics as FDA Prioritizes Govorestat, Signaling Strong Market Prospects

March 1, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Applied Therapeutics Amid Favorable Drug Approval Prospects and Strong Financial Position

February 28, 2024 | marketwatch.com

Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round

February 28, 2024 | markets.businessinsider.com

Applied Therapeutics Rallies After Announcing Private Placement Of Shares

February 28, 2024 | msn.com

FDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic Disorder

February 28, 2024 | investorplace.com

Why Is Applied Therapeutics (APLT) Stock Up 59% Today?

See More Headlines

Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:APLT
CUSIP: N/A
CIK: 1697532
Web: www.appliedtherapeutics.com
Phone: (212) 220-9226
Fax: N/A
Employees: 25
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $11.60
High Stock Price Target: $14.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +140.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,760,000.00
Net Margins: N/A
Pretax Margin: -1,198.47%
Return on Equity: N/A
Return on Assets: -275.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.76
Quick Ratio: 0.76

Sales & Book Value

Annual Sales: $9.99 million
Price / Sales: 51.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.20) per share
Price / Book: -24.15

Miscellaneous

Outstanding Shares: 105,890,000
Free Float: 85,663,000
Market Cap: $511.45 million
Optionable: Optionable
Beta: 1.81

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Shoshana Shendelman Ph.D. (Age 45)
Chair of the Board of Directors, Founder, President, CEO & Secretary
Comp: $813.47k
Mr. Les D. Funtleyder (Age 53)
CFO, Principal Financial Officer & Independent Director
Comp: $40k
Dr. Riccardo Perfetti M.D. (Age 63)
Ph.D., Chief Medical Officer
Comp: $858k
Mr. Adam Hansard (Age 47)
Chief Commercial Officer
Comp: $742.66k
Mr. Constantine Chinoporos (Age 58)
COO & Chief Business Officer
Ms. Catherine Thorpe (Age 60)
Chief Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Applied Therapeutics stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLT shares.
View APLT analyst ratings or view top-rated stocks.
What is Applied Therapeutics' stock price target for 2024?: 5 analysts have issued twelve-month price targets for Applied Therapeutics' stock. Their APLT share price targets range from $7.00 to $14.00. On average, they expect the company's stock price to reach $11.60 in the next year. This suggests a possible upside of 140.2% from the stock's current price.
View analysts price targets for APLT or view top-rated stocks among Wall Street analysts.
How have APLT shares performed in 2024?: Applied Therapeutics' stock was trading at $3.35 on January 1st, 2024. Since then, APLT shares have increased by 44.2% and is now trading at $4.83.
View the best growth stocks for 2024 here.
Are investors shorting Applied Therapeutics?: Applied Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,980,000 shares, an increase of 31.4% from the March 15th total of 3,790,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is presently 2.4 days.
View Applied Therapeutics' Short Interest.
When is Applied Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our APLT earnings forecast.
How were Applied Therapeutics' earnings last quarter?: Applied Therapeutics, Inc. (NASDAQ:APLT) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.18. The firm had revenue of ($0.67) million for the quarter.

What ETF holds Applied Therapeutics' stock?: Simplify Propel Opportunities ETF holds 2,817,505 shares of APLT stock, representing 14.71% of its portfolio.
What other stocks do shareholders of Applied Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and RTX (RTX).
When did Applied Therapeutics IPO?: Applied Therapeutics (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.
How do I buy shares of Applied Therapeutics?: Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APLT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Applied Therapeutics (APLT) Stock Price, News & Analysis

Applied Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Applied Therapeutics Stock (NASDAQ:APLT)

APLT Stock Price History

APLT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

APLT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™